BCL2 and cancer: Thus, ATF2 appear to be a promising apoptotic target for the therapeutic agents to work on, whereby targeting ATF2 to tumor cells suppressing proapoptotic proteins like Bcl-2 and HK1 would reduce the mechanisms for cancer cells self defense, accordingly, promoting cellular sensitivity to therapeutic ahents through increasing apoptosis.